FOXP3 and cancer: Notably, the population of liver-resident Tregs (CD4+Foxp3+) expands during MASH, with FOXP3+ Tregs demonstrating the ability to suppress the proliferation and activity of CD8+ T cells and Th1 cells, which play a crucial role in immune surveillance against cancer.